文献速递前列腺癌

基于数字病理的多模态人工智能架构在NRG/RTOG 9902 3期试验中的外部验证

External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial.
PubMed 文献 · Eur Urol Oncol · 2024-02-01

本研究在NRG/RTOG 9902 3期试验的318例高危局限性前列腺癌患者中,外部验证两个先前锁定的多模态人工智能预后模型对远处转移和前列腺癌特异性死亡的预测能力。结果显示,DM MMAI算法与远处转移风险独立相关(sHR=2.33,95%CI 1.60-3.38,p<0.001),PCSM MMAI算法与前列腺癌特异性死亡风险独立相关(sHR=3.54,95%CI 2.38-5.28,p<0.001)。

要点

  • DM MMAI每增加1个标准差,远处转移风险sHR=2.33(95%CI 1.60-3.38,p<0.001)。
  • PCSM MMAI每增加1个标准差,前列腺癌特异性死亡风险sHR=3.54(95%CI 2.38-5.28,p<0.001)。
  • DM MMAI评分较低75%患者5年和10年DM率为4%和7%,最高四分位组平均为19%和32%(p<0.001)。

核心结论

  • 在既往已发生远处转移和前列腺癌特异性死亡的高危局限性前列腺癌人群中,MMAI预后模型可在临床和病理变量之外进一步进行风险分层。

研究设计与样本

  • 外部验证队列纳入NRG/RTOG 9902 3期随机对照试验中318例有可用组织病理学的局限性高危前列腺癌患者,试验入组397例中337例(85%)有可用切片,其中19例(5.6%)因图像质量差而失败。

主要发现

  • DM MMAI算法与远处转移风险显著且独立相关(sHR=2.33,95%CI 1.60-3.38,p<0.001)。
  • PCSM MMAI算法与前列腺癌特异性死亡风险显著且独立相关(sHR=3.54,95%CI 2.38-5.28,p<0.001)。
  • DM MMAI评分较低75%患者的估计5年和10年DM率为4%和7%,最高四分位组平均5年和10年DM率为19%和32%(p<0.001)。
  • PCSM MMAI算法观察到类似结果。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate risk stratification is critical to guide management decisions in localized prostate cancer (PCa). Previously, we had developed and validated a multimodal artificial intelligence (MMAI) model generated from digital histopathology and clinical features. Here, we externally validate this model on men with high-risk or locally advanced PCa treated and followed as part of a phase 3 randomized control trial. OBJECTIVE: To externally validate the MMAI model on men with high-risk or locally advanced PCa treated and followed as part of a phase 3 randomized control trial. DESIGN, SETTING, AND PARTICIPANTS: Our validation cohort included 318 localized high-risk PCa patients from NRG/RTOG 9902 with available histopathology (337 [85%] of the 397 patients enrolled into the trial had available slides, of which 19 [5.6%] failed due to poor image quality). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Two previously locked prognostic MMAI models were validated for their intended endpoint: distant metastasis (DM) and PCa-specific mortality (PCSM). Individual clinical factors and the number of National Comprehensive Cancer Network (NCCN) high-risk features served as comparators. Subdistribution hazard ratio (sHR) was reported per standard deviation increase of the score with corresponding 95% confidence interval (CI) using Fine-Gray or Cox proportional hazards models. RESULTS AND LIMITATIONS: The DM and PCSM MMAI algorithms were significantly and independently associated with the risk of DM (sHR [95% CI] = 2.33 [1.60-3.38], p < 0.001) and PCSM, respectively (sHR [95% CI] = 3.54 [2.38-5.28], p < 0.001) when compared against other prognostic clinical factors and NCCN high-risk features. The lower 75% of patients by DM MMAI had estimated 5- and 10-yr DM rates of 4% and 7%, and the highest quartile had average 5- and 10-yr DM rates of 19% and 32%, respectively (p < 0.001). Similar results were observed for the PCSM MMAI algorithm. CONCLUSIONS: We externally validated the prognostic ability of MMAI models previously developed among men with localized high-risk disease. MMAI prognostic models further risk stratify beyond the clinical and pathological variables for DM and PCSM in a population of men already at a high risk for disease progression. This study provides evidence for consistent validation of our deep learning MMAI models to improve prognostication and enable more informed decision-making for patient care. PATIENT SUMMARY: This paper presents a novel approach using images from pathology slides along with clinical variables to validate artificial intelligence (computer-generated) prognostic models. When implemented, clinicians can offer a more personalized and tailored prognostic discussion for men with localized prostate cancer.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Ross AE, Zhang J, Huang HC, et al. External Validation of a Digital Pathology-based Multimodal Artificial Intelligence Architecture in the NRG/RTOG 9902 Phase 3 Trial. Eur Urol Oncol. 2024. PMID: 38302323. doi:10.1016/j.euo.2024.01.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。